Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

v3.22.1
MEZZANINE EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Stock issued during period, shares, new issues     11,413  
Stock issued during period, value, new issues     $ 5,000  
Payments of stock issuance costs   $ 387,000  
Proceeds from issuance or sale of equity $ 23,000,000.0      
Payments for construction in process $ 7,300,000      
Common Stock [Member]        
Stock issued during period, shares, new issues   375,000    
Stock issued during period, value, new issues   $ 274,000    
Class of warrant or right, number of securities called by warrants or rights 32,282,708 26,351,571 32,282,708  
Maximum [Member] | Common Stock [Member]        
Warrant exercise price   $ 5.50    
Hadron Healthcare Master Fund [Member] | Warrant [Member]        
Warrant exercise price $ 1.087   $ 1.087  
Fair value adjustment of warrants $ 9,500,000      
Payments of stock issuance costs $ 387,000      
Hadron Healthcare Master Fund [Member] | Maximum [Member] | Common Stock [Member]        
Class of warrant or right, number of securities called by warrants or rights 15,540,540   15,540,540  
3M Note [Member]        
Repayments of debt and lease obligation $ 15,700,000      
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Warrant [Member]        
Warrants term 4 years   4 years  
Series B Convertible Preferred Stock [Member]        
Shares issued, price per share   3.00    
Preferred stock, convertible conversion price   $ 3.00    
Preferred stock conversion, description   the Company has the option to convert all, but not less than all, shares of Series B convertible preferred stock into common stock at a conversion price of $3.00 if the daily volume weighted average price of common stock (the “VWAP”) exceeds $4.00 per share for at least twenty consecutive trading days prior to the date on which the Company gives notice of such conversion to the Series B Holders    
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price Less Than Or Equal To $0.50 Per Share [Member]        
Preferred stock conversion, description   If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share    
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price Greater Than $0.50 Per Share [Member]        
Preferred stock conversion, description   If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the sixty-day VWAP per share and pay cash to the Series B Holders at the difference between $3.00 per share and the sixty-day VWAP per share    
Series B Convertible Preferred Stock [Member] | Exchange Agreement [Member] | Two Institutional Shareholders [Member]        
Debt instrument, face amount       $ 4,400,000
Conversion of stock, shares converted       4,908,333
Series C Convertible Preferred Stock [Member] | Hadron Healthcare Master Fund [Member] | Warrant [Member]        
Stock issued during period, shares, new issues 6,216,216      
Series C Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member]        
Shares issued, price per share $ 3.70   $ 3.70  
Stock issued during period, value, new issues $ 23,000,000.0      
Series C Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Maximum [Member]        
Stock issued during period, shares, new issues 46,000,000.0